evolcSign inStart free
Menu

Primoceler

Hermetic glass packaging and laser bonding for active implantable device electronics, from prototype to series production

Tampere, FinlandFounded 2010primoceler.comWebsite technologies

+ Add to sales board

Highlights

  • New on EvolcAdded 2026-10-28

About Primoceler

Primoceler designs hermetic glass packaging for the electronics inside active implantable devices. Its core technique is laser bonding of glass, which seals components without adhesives or damaging heat, and glass passes RF and light so devices can be miniaturised. Services span feasibility through series production and ongoing supply, organised in a gated development path called the Proteon Framework.

The company works with developers of implantable devices, from startups to established device makers, as a development and manufacturing partner. It describes its quality system as ISO 9001 certified.

Primoceler is registered in Tampere, Finland, and was founded in 2010.

Product: Hermetic glass packaging and laser-bonded sealing for electronics in active implantable devices, with development and series manufacturing.

Jobs at Primoceler

No open positions listed right now.

More biotech & pharma companies

  • Probiont

    Develops organ-on-a-chip solutions to test cancer immunotherapy efficacy for personalized treatment assessment
    Helsinki, FinlandBiotech & pharmaFounded 2021
    New on Evolc

  • Puro Analytics

    EDNA biodiversity monitoring for organisations: species detection, fish and forest surveys, lab analysis and reports
    Helsinki, FinlandBiotech & pharmaFounded 2025
    Young companyNew on Evolc

  • Rappta Therapeutics

    Develops first-in-class anti-cancer molecular glues that reactivate the tumor suppressor PP2A, for oncology drug development
    Helsinki, FinlandBiotech & pharmaFounded 2019
    New on Evolc

  • Reagena

    Diagnostic tests and laboratory reagents for clinical, biotechnology, pharmaceutical and research organizations
    Toivala, FinlandBiotech & pharmaFounded 2012
    New on Evolc

  • ReBio Technologies

    Develops targeted, locally delivered drug conjugates for ocular cancers, starting with uveal melanoma
    Raisio, FinlandBiotech & pharmaFounded 2015
    New on Evolc

  • Replicon Health

    Develops oral drug candidate RH013001 for aging-related degenerative diseases and seeks pharma partners to bring it to market
    Espoo, FinlandBiotech & pharmaFounded 2002
    New on Evolc

All biotech & pharma companies →

Website technologies

Older, unverified list. Detection dates and supporting evidence are not yet available.

  • Next.js
  • React
  • Tailwind CSS
  • Vercel